Zomedica Corp Stock Price Target Forecast, (ZOM) Prediction 2022, 2023, 2025, 2030

27 December, 2021

You Should Consider Zomedica Corp. (AMEX: ZOM) As A Bargain Stock.

Trade data for Zomedica Corp. (AMEX:ZOM).

As observed in intraday transactions today, ZOM is instantly in the green. The performance over the last five days has been red, with action -5.15 percent. The climb to weekly highs of 0.3666 on Thursday, 12/23/21 increased the stock’s daily price by 0.29 percent. The company’s stock has gained 51.78 percent year to date, with a 5-day performance of -5.15 percent in the negative. However, Zomedica Corp. (AMEX:ZOM) is down -19.09 percent over the last 30 days. We can observe that 88.9 million shares were sold at a short interest cover period of 4.36 days when we look at the short shares.

Wall Street analysts’ consensus price objective for the company is $1.20, implying a 70.83 percent gain from its current market value for bulls. ZOM’s predicted low is $1.20, with $1.20 as the goal high, according to analyst forecasts. To reach the anticipated high, the stock must drop -242.86 percent from its present position, while to reach the expected low, the stock must rise -242.86 percent.

Estimates and predictions from Zomedica Corp. (ZOM).

Zomedica Corp.’s revenue for the quarter ending June 2021 is expected to be $1.1 million, according to 1 analyst.

Data reveals that the company’s earnings have grown at an annual pace of 8.90 percent over the last five years. Earnings for Zomedica Corp. are expected to rise by 75.10 percent in 2021.

Dividends from ZOM

Between August 09 and August 13, Zomedica Corp. is likely to announce its next quarterly results report.

marketingsentinel.com is the source of this information.

December 02, 2021

ZOM Stock Price Prediction 2021, 2022, 2025, and 2030 – ZOM Stock Forecast 2021

ZOM Stock Price Forecast 2021 and 2022 – Key Drivers

If you buy stocks on a regular basis, you know how important it is to know about the company you’re investing in and the factors that might influence the share price. In terms of ZOM, it’s critical to understand how the company operates, as it’s still in the early stages of development. So, with that in mind, let’s talk about ZOM and the factors that influence its stock price.

Zomedica Corp. (ZOM) is an Ann Arbor-based veterinary health firm that develops and sells point-of-care diagnostics. These goods and services allude to a method for detecting medical abnormalities in companion animals in real time, which is significantly faster than the present method, allowing animals to be treated more quickly. The number of individuals who own pets has increased dramatically since the COVID-19 outbreak, therefore this appears to be a lucrative market for ZOM.

The existing animal healthcare system entails a pet owner sending their animal to the veterinarian, who then takes blood samples, which are then submitted to a lab for analysis. As you may expect, this procedure takes a long time and might aggravate an animal’s illness. TRUFORMA, a platform that helps diagnose thyroid abnormalities in dogs and cats, is one example of Zomedica’s efforts to enhance this procedure.

Veterinarians’ capacity to run tests at the point of treatment has the potential to transform the industry as we know it. TRUFORMA was only released in March 2021, thus revenue stats aren’t exactly impressive right now. However, as ZOM grows its customer base and develops new diagnostic tools, the company’s future looks better.

ZOM Stock Price Prediction – Short-Term Prospects

Today let’s talk about if ZOM is a good stock to purchase now for the short term. ZOM is now trading below the 50-day and 200-day moving averages, as shown in the price chart. This is a negative indication since these signs might operate as a barrier level, preventing the price from rising. Furthermore, price continues to make lower highs and lower lows, which is typical of a decline.

There appears to be a solid support level around $0.45, which has previously maintained the price steady. This was tested in August and was quickly rejected, resulting in a large price hike. As we get closer to that region, any significant rejection might be a bullish indication, so keep an eye out for it.

The technicals, on the other hand, do not give the complete tale. Zomedica is still in its early stages of development, as we said previously. As a result, the financials don’t seem promising – but that’s to be anticipated. Between January and June of this year, the firm made a total of $29,800 in sales. During the same year, the firm incurred significant R&D costs, resulting in a net loss of nearly $8.7 million for Zomedica.

This may appear to be a negative situation on the surface, but it is really rather frequent. Companies frequently raise cash and subsequently operate at a loss while still developing, thus Zomedica is not unusual in this regard. However, now that Zomedica’s TRUFORMA product has been released to the market, investors want the business to start producing large income streams to demonstrate that the product is in demand.

Because Zomedica is now losing money, EPS statistics are negative, which doesn’t tell us anything. Similarly, the P/E ratio of ZOM is meaningless, making it difficult to compare the business to others in its industry. Overall, Zomedica’s short-term prognosis is anticipated to be somewhat neutral, since the firm is more likely to grow in the long run.

ZOM Stock Price Prediction – Long-Term Prospects

When investing in small-cap companies, much as when buying cryptocurrencies, having a long-term price goal is critical. Now that Zomedica is profitable, it’s probable that the firm will receive greater attention. Even if the diagnostic equipment are cutting-edge, if there is no market for them, all of the research and development will be for naught.

There are approximately 120,000 veterinary clinics in the United States, therefore Zomedica has a sizable target market to pursue. Furthermore, if there is sufficient demand, the firm may expand into Canada and Europe. When you throw in the additional gadgets that Zomedica plans to create, it’s a recipe for speculative investors to get excited about.

According to the Financial Times, Zomedica now has 979.73 million shares outstanding. This translates to a market capitalization of $504.07 million, which is tremendous for a firm that is still in the pre-revenue stage. It’s difficult to explain this price right now, which may be one of the reasons for the market’s current bearishness.

The fact that Zomedica has switched to a ‘direct to consumer’ strategy is an interesting part of the company’s business model. This eliminates the need for a distributor, allowing Zomedica to focus on marketing and raising awareness of the product. Once more devices are added to Zomedica’s portfolio, this direct selling strategy will provide them more price flexibility, resulting in higher future revenues.

economywatch.com is the source of this information.

October 13, 2021

Stock outlook for Zomedica (ZOM): A long wait for profitability threatens the stock’s sustainability.

Prediction of Zomedica’s stock price

Despite decreases in R&D expenses and the potential of future income sources, the tiny number of experts that make a ZOM stock forecast remain gloomy about the company’s prospects.

One of the few investment banks giving coverage looks to be HC Wainwright. On November 16, 2020, its analyst, Swayampakula Ramkanth, gave Zomedica a ‘buy’ recommendation and decreased the price objective from $0.50 to $0.30.

Gov Capital, one of the algorithm-based forecasting firms, has a one-year price projection of $0.0185, a 96.75 percent drop. Such a drop would put the firm on the verge of being delisted.

Wallet Investor is more positive, but still expects a decrease. It predicts a one-year price objective of $0.289 for the stock.

With a 0.35 price prediction for October 2022, LeoProphet is pricing the stock even higher.

It’s worth noting that projections are frequently incorrect. Before making any investment or trading choice, you should always undertake your own research.

capital.com is the source for this information.

6 MAY 2021,

Zomedica Stock Forecast for 2025: Will ZOM Continue to Rise or Fall?

All of the penny names, particularly those boosted by WallStreetBets, have seen a carnage. While the short squeezes that WallStreetBets initiated can influence short-term price movement, companies tend to trade according to their underlying worth in the medium to long term.

Forecast for the ZOM stock in 2025

If we extrapolate the estimate out to 2025, the ZOM stock seems promising. I have stated that ZOM stock appears to be an excellent long-term investment. My only reservation was about the cost. The stock has a market value of $825 million and is currently trading below $0.90. While we don’t know how much cash was spent in the first quarter, total cash should be approximately $250 million, implying an EV of $575 million.

ZOM is now putting its Truforma point-of-care equipment on the market, which is aimed at veterinary practitioners. The platform would aid in the detection of thyroid and adrenal illnesses in dogs and cats.

According to Zomedica’s filing, the market potential for companion animal diagnostics is estimated to grow from $1.7 billion in 2019 to $2.8 billion in 2024, using MarketsandMarkets statistics. The increasing pet-care business in the United States and throughout the world presents a promising potential for Zomedica.

Will the price of ZOM go up or down?

In the short term, ZOM stock may be vulnerable to a drop. However, the stock may be approaching its bottom presently. It might be a winner if you are a patient investor who can hold the stock for the long term.

The company’s financial sheet appears to be in good shape, and it has more cash than it requires. I wouldn’t be shocked if it considers purchases as a way to put the capital to good use. Truforma appears to be a strong pick in terms of product.

If Zomedica can market Truforma effectively, the stock might be a solid investment. It is, however, a high-risk venture, as is the case with all organisations in the pre-revenue stage. Risk and reward seem to go hand in hand in markets.

marketrealist.com is the source of this information.

Disclaimer:The views and investment tips expressed by investment expert on Stock consultant bihar are Sourced From Brokerage Firms Research Reports & Market Experts Opinion. We advises users to consult your investment advisor before taking any decisions. Our Website Contain Demat Account & Algo Trading affliate Link. If You’ll Register Through Our Link We May Get Profit.

More US Stocks Forecast Updates:

We will be happy to hear your thoughts

Leave a reply

Stock Consultant Bihar